<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573621</url>
  </required_header>
  <id_info>
    <org_study_id>GECO1</org_study_id>
    <nct_id>NCT04573621</nct_id>
  </id_info>
  <brief_title>Pelvic Drain After Rectal Resection for Mid-low Rectal Cancer</brief_title>
  <acronym>GECO1</acronym>
  <official_title>Pelvic Drain After Rectal Resection for Mid-low Rectal Cancer: a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This RCT aims at assessing the effects of a pelvic drain after total mesorectal excision for&#xD;
      mid-low rectal cancer on the rates of pelvic sepsis and anastomotic leaks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2-arm, non-inferiority RCT. Patients undergoing total mesorectal excision for&#xD;
      mid-low rectal cancer will be randomly assigned into two groups:&#xD;
&#xD;
        -  pelvic drain&#xD;
&#xD;
        -  no pelvic drain. Patients will be followed-up to assess the rates of anastomotic leaks,&#xD;
           pelvic sepsis and secondary outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The assessor will not know whether the patient received a drain or not</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with pelvic sepsis</measure>
    <time_frame>0-30 days postoperatively</time_frame>
    <description>anastomotic leak or pelvic collections clinically or radiologically detected</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Management of pelvic sepsis</measure>
    <time_frame>0-30 days postoperatively</time_frame>
    <description>Type of management (medical, rediological, surgical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>0-30 days postoperatively</time_frame>
    <description>Overall postoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT scan or imaging needed</measure>
    <time_frame>0-30 days postoperatively</time_frame>
    <description>Necessity of performing unscheduled imaging tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with postoperative ileus</measure>
    <time_frame>0-30 days postoperatively</time_frame>
    <description>Postoperative ileus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic delay for a leak</measure>
    <time_frame>0-30 days postoperatively</time_frame>
    <description>Days between surgery and leak detection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of postperative stay</measure>
    <time_frame>0-30 days postoperatively or until discharge</time_frame>
    <description>Days of stay after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to flatus and bowel movement</measure>
    <time_frame>0-30 days postoperatively</time_frame>
    <description>Days between surgery and flatus/faeces</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stoma presence at 1-year follow-up</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Necessity of maintaining the diverting ileostomy at 1-year follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late pelvic collections</measure>
    <time_frame>up to 60 days after surgery</time_frame>
    <description>Presence of pelvic collections detected at longer follow-up intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small bowel obstruction</measure>
    <time_frame>up to 60 days after surgery</time_frame>
    <description>Mechanical small bowel obstruction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life associated with a drain</measure>
    <time_frame>30 days postoperatively</time_frame>
    <description>Visual Analogue Scale 0-10 (higher score means better outcome) score of postoperative pain and wound complaints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any complications associated with drain removal after surgery</measure>
    <time_frame>up to 60 days after surgery</time_frame>
    <description>Safety of drain removal after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">518</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Pelvic drain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placement of a pelvic drain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No pelvic drain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No pelvic drain placed</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pelvic drain</intervention_name>
    <description>A pelvic drain is placed</description>
    <arm_group_label>Pelvic drain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No pelvic drain is placed</intervention_name>
    <description>A pelvic drain is not placed</description>
    <arm_group_label>No pelvic drain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female, 18 year-of-age or above&#xD;
&#xD;
          -  Mid or low rectal cancer&#xD;
&#xD;
          -  Anastomosis below the peritoneal reflection&#xD;
&#xD;
          -  Total mesorectal excision (TME)&#xD;
&#xD;
          -  Capability to understand the study&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For women, pregnancy&#xD;
&#xD;
          -  Chronic kidney failure or hepatic failure, immunodepression, malnoutrition&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Partial mesorectal excision&#xD;
&#xD;
          -  Abdominoperineal excision&#xD;
&#xD;
          -  Multivisceral resections&#xD;
&#xD;
          -  Emergency surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eloy Espín-Basany</last_name>
    <phone>932746000</phone>
    <phone_ext>6587</phone_ext>
    <email>eespin@vhebron.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital General Universitario Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona, Spain</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eloy Espín Basany, MD PhD</last_name>
      <phone>934 893 000</phone>
      <phone_ext>6587</phone_ext>
      <email>eespin@vhebron.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

